Jounce Therapeutics, Inc. — Form D
Jounce Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2015-04-29. The offering totals $56.0M, of which $56.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2015-04-29
- Form: D
- Accession: 0001640455-15-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $56.0M
- Amount sold: $56.0M
- Investors: 14
- Date of first sale: 2015-04-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-238833
Issuer
- Name: Jounce Therapeutics, Inc.
- CIK: 0001640455
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139
- Phone: 857-259-3840
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Anna L Barry | Executive Officer | Cambridge, MA |
| Kim C Drapkin | Executive Officer | Boston, MA |
| Richard Murray | Director | South San Francisco, CA |
| Richard Murray | Executive Officer | South San Francisco, CA |
| Cary G Pfeffer | Director | Baltimore, MD |
| Kimberlee C Drapkin | Executive Officer | Seattle, WA |
| Luis A. G Diaz, Jr. | Director | Cambridge, MA |
| Duncan G Higgons | Director | Cambridge, MA |
| Robert G Iannone | Director | Cambridge, MA |
| Robert G Kamen | Director | Cambridge, MA |
| Robert G Tepper | Director | Cambridge, MA |
| Perry G Karsen | Director | Cambridge, MA |
| Elizabeth G Trehu | Executive Officer | Cambridge, MA |
| Hugh M Cole | Executive Officer | Cambridge, MA |
| Barbara G Duncan | Director | Cambridge, MA |
Other filings by this issuer (1)
More